Recent News

• 05.05.2025 - UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates
• 05.05.2025 - UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates
• 05.01.2025 - UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting
• 05.01.2025 - UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting
• 05.01.2025 - UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting
• 04.23.2025 - UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME
• 04.23.2025 - UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME
• 04.22.2025 - UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates
• 04.22.2025 - UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates
• 04.22.2025 - UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

Recent Filings

• 04.22.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.22.2025 - 8-K Current report
• 04.22.2025 - EX-99.1 EX-99.1
• 04.11.2025 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]
• 04.04.2025 - 8-K Current report
• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.03.2025 - 144 Report of proposed sale of securities
• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.03.2025 - 144 Report of proposed sale of securities